Literature DB >> 9138675

Inhibition of the constitutive activity of human 5-HT1A receptors by the inverse agonist, spiperone but not the neutral antagonist, WAY 100,635.

A Newman-Tancredi1, C Conte, C Chaput, M Spedding, M J Millan.   

Abstract

At recombinant human 5-hydroxytryptamine (5-HT)5-HT1A receptors expressed in Chinese hamster ovary cells (CHO-5-HT1A), 5-carboxamidotryptamine (5-CT), acted as a full agonist (relative to 5-HT = 100%) for stimulation of receptor-mediated [35S]-GTP gamma S (guanylyl 5'-[gamma-thio]-tryphosphate) binding. In contrast, spiperone inhibited basal [35S]-GTP gamma S binding by 30.2% (IC50 = 55.5 nM) in CHO-5-HT1A membranes but not in control untransfected membranes. The antagonist, N-[2-[4-(2-methoxyphenyl) -1-piperazinyl]ethyl]-N-(2-pyridinyl)-cyclohexane-carboxamide (WAY 100,635), blocked both 5-CT-induced stimulation and spiperone-induced inhibition of [35S]-GTP gamma S binding without itself modifying [35S]-GTP gamma S binding. It is concluded that, in this heterologous expression system, 5-HT1A receptors display 'constitutive' activation of G-proteins and that spiperone displays inverse agonist activity whereas WAY 100,635 acts as a 'neutral' antagonist at this site.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9138675      PMCID: PMC1564555          DOI: 10.1038/sj.bjp.0701025

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  12 in total

Review 1.  Inverse agonism at G protein-coupled receptors: (patho)physiological relevance and implications for drug discovery.

Authors:  R A de Ligt; A P Kourounakis; A P IJzerman
Journal:  Br J Pharmacol       Date:  2000-05       Impact factor: 8.739

Review 2.  Review: amino acid domains involved in constitutive activation of G-protein-coupled receptors.

Authors:  P J Pauwels; T Wurch
Journal:  Mol Neurobiol       Date:  1998       Impact factor: 5.590

3.  Differential modulation by GTPgammaS of agonist and inverse agonist binding to h5-HT(1A) receptors revealed by [3H]-WAY100,635.

Authors:  A Newman-Tancredi; L Verrièle; M J Millan
Journal:  Br J Pharmacol       Date:  2001-01       Impact factor: 8.739

Review 4.  5-hydroxtryptamine receptors in systemic hypertension: an arterial focus.

Authors:  Stephanie W Watts; Robert Patrick Davis
Journal:  Cardiovasc Ther       Date:  2011-02       Impact factor: 3.023

5.  Inverse agonist activity of pirenzepine at M2 muscarinic acetylcholine receptors.

Authors:  L Daeffler; F Schmidlin; J P Gies; Y Landry
Journal:  Br J Pharmacol       Date:  1999-03       Impact factor: 8.739

6.  Inverse agonist and neutral antagonist actions of synthetic compounds at an insect 5-HT1 receptor.

Authors:  B Troppmann; S Balfanz; A Baumann; W Blenau
Journal:  Br J Pharmacol       Date:  2010-03-03       Impact factor: 8.739

7.  Differential serotonergic modulation across the main and accessory olfactory bulbs.

Authors:  Zhenbo Huang; Nicolas Thiebaud; Debra Ann Fadool
Journal:  J Physiol       Date:  2017-03-31       Impact factor: 5.182

8.  Inverse agonism and neutral antagonism at a constitutively active alpha-1a adrenoceptor.

Authors:  J Zhu; T Taniguchi; R Takauji; F Suzuki; T Tanaka; I Muramatsu
Journal:  Br J Pharmacol       Date:  2000-10       Impact factor: 8.739

9.  Comparison of hippocampal G protein activation by 5-HT(1A) receptor agonists and the atypical antipsychotics clozapine and S16924.

Authors:  A Newman-Tancredi; J-M Rivet; D Cussac; M Touzard; C Chaput; L Marini; M J Millan
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2003-08-16       Impact factor: 3.000

Review 10.  Cannabinoid-Induced Hyperemesis: A Conundrum-From Clinical Recognition to Basic Science Mechanisms.

Authors:  Nissar A Darmani
Journal:  Pharmaceuticals (Basel)       Date:  2010-07-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.